Sep 08, 09
|
| NEW STORY |
| 06:00 ET |
LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
|
|
Mar 18, 08
|
| 12:05 ET |
LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series 'C' Financing Round
|
|
Sep 18, 07
|
| 06:00 ET |
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
|
|
May 01, 07
|
| 21:08 ET |
LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
|
|
Apr 03, 07
|
| 09:48 ET |
LigoCyte Pharmaceuticals Initiates U.S. Clinical Trial of Norovirus Vaccine
|
|
Jan 03, 07
|
| 06:30 ET |
Donald P. Beeman Is Appointed Chairman of the Board of Directors at LigoCyte Pharmaceuticals, Inc.
|
|
Dec 14, 06
|
| 06:30 ET |
LigoCyte Pharmaceuticals Announces the Addition of Dr. Donald deBethizy to Their Board of Directors
|
|
Jul 06, 06
|
| 06:00 ET |
LigoCyte Pharmaceuticals Awarded an Additional $2.3M Department of Defense Contract to Continue the Preclinical Development of Their 3rd Generation, Mucosal Anthrax Vaccine
|
|
May 18, 06
|
| 06:00 ET |
LigoCyte Pharmaceuticals Welcomes Don Beeman as New CEO
|
|
Oct 03, 05
|
| 05:00 ET |
LigoCyte Pharmaceuticals Receives $4.6M NIH Biodefense Challenge Grant for Intranasal Anthrax Vaccine
|
|
|